Similar articles

• The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis.

  Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V. Jardine MJ, et al. BMJ. 2012 Jun 13;344:e3533. doi: 10.1136/bmj.e3533. BMJ. 2012. PMID: 22695899 Free PMC article. Review.
• Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease.

  Clarke R, Collins R. Clarke R, et al. J Cardiovasc Risk. 1998 Aug;5(4):249-55. J Cardiovasc Risk. 1998. PMID: 9919473 No abstract available.
• Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials.

  Qin X, Huo Y, Xie D, Hou F, Xu X, Wang X. Qin X, et al. Clin Nutr. 2013 Oct;32(5):722-7. doi: 10.1016/j.clnu.2012.12.009. Epub 2012 Dec 28. Clin Nutr. 2013. PMID: 23313356
• The homocysteine paradox.

  Rodionov RN, Lentz SR. Rodionov RN, et al. Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1031-3. doi: 10.1161/ATVBAHA.108.164830. Arterioscler Thromb Vasc Biol. 2008. PMID: 18495971 Free PMC article. No abstract available.
• Homocysteine and renal disease.

  van Guldener C, Robinson K. van Guldener C, et al. Semin Thromb Hemost. 2000;26(3):313-24. doi: 10.1055/s-2000-8407. Semin Thromb Hemost. 2000. PMID: 11011849 Review.